Blood gene signatures may help predict lymphoma treatment response

Simple blood tests may soon help veterinarians identify which dogs with diffuse large B-cell lymphoma are more likely to respond well to chemoimmunotherapy, according to a new Tufts-led study. Researchers analyzed serial peripheral blood mononuclear cell samples from pet dogs enrolled in a clinical trial and found that higher post-treatment expression of CD1E and CCL14 was associated with long-term survival, while interferon-stimulated gene signatures and several immune-skewing genes were linked to earlier relapse and shorter survival. The work builds on an earlier Tufts study from the same trial showing that baseline tumor gene-expression patterns varied by treatment arm and could help predict response to specific drug combinations. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the study points toward a more practical, less invasive way to stratify canine lymphoma patients during treatment rather than relying only on tumor sampling or waiting for clinical relapse. The authors frame the approach as a proof of principle for blood-based immune monitoring that could eventually support earlier treatment adjustments for poor responders, although the work remains preliminary and was conducted in dogs receiving a specific non-randomized regimen that combined a caninized anti-CD20 antibody, low-dose doxorubicin, and one of three targeted agents: RV1001, KPT-9274, or TAK-981. More broadly, it fits with a growing push in veterinary oncology toward liquid biopsy and other blood-based tools for prognosis and monitoring. (pmc.ncbi.nlm.nih.gov)

What to watch: The next step is validation in larger, independent cohorts and translation into clinic-friendly qPCR assays that could be used at the point of care to flag likely poor responders before relapse becomes clinically obvious. (pmc.ncbi.nlm.nih.gov)